Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;5(5):325-42.
doi: 10.2165/00151829-200605050-00004.

Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy

Affiliations
Review

Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy

Jeffrey C Horowitz et al. Treat Respir Med. 2006.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually fatal pulmonary disease for which there are no proven drug therapies. Anti-inflammatory and immunosuppressive agents have been largely ineffective. The precise relationship of IPF to other idiopathic interstitial pneumonias (IIPs) is not known, despite the observation that different histopathologic patterns of IIP may coexist in the same patient. We propose that these different histopathologic 'reaction' patterns may be determined by complex interactions between host and environmental factors that alter the local alveolar milieu. Recent paradigms in IPF pathogenesis have focused on dysregulated epithelial-mesenchymal interactions, an imbalance in T(H)1/T(H)2 cytokine profile and potential roles for aberrant angiogenesis. In this review, we discuss these evolving concepts in disease pathogenesis and emerging therapies designed to target pro-fibrogenic pathways in IPF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Idiopathic interstitial pneumonias (IIPs) represent an overlapping spectrum of inflammatory and fibrotic tissue reactions or histopathologic patterns in response to an “unknown” injury. At one end of the spectrum are IIPs marked predominantly by diffuse inflammatory cell infiltration; these IIPs tend to be more responsive to anti-inflammatory and immunosuppressive drug therapy. At the other end of the spectrum are IIPs characterized by fibrosis with minimal inflammation; these disease processes tend to have poor responses to currently available pharmacologic agents. Host factors (such as age and genetic polymorphisms) in combination with environmental factors (such as exposure to infectious agents and cigarette smoke) likely determine the resulting histopathological reaction patterns. DIP, desquamative interstitial pneumonia; RB-ILD, respiratory bronchiolitis associated-interstitial lung disease; COP, cryptogenic organizing pneumonia; NSIP, non-specific interstitial pneumonia; AIP, acute interstitial pneumonia; UIP, usual interstitial pneumonia.
Figure 2
Figure 2
The pathogenesis of IPF is complex and three major hypotheses or paradigms for the pathogenesis of IPF have emerged: dysregulated epithelial-mesenchymal interactions, aberrant angiogenesis and the TH1/TH2 cytokine imbalance. Epithelial-mesenchymal interactions between altered epithelial and mesenchymal phenotypes results in dysregulated interactions between these cellular compartments. In response to an unknown stimulus, alveolar epithelial cells in IPF develop a phenotype characterized by increased apoptosis, dysregulated proliferation, impaired regeneration/differentiation and perhaps impaired migration. Alveolar epithelial cells elaborate increased TGF-β1 and endothelin-1 along with decreased levels of PGE2. Mesenchymal cells in this alveolar microenvironment acquire a contractile, synthetically active myofibroblast phenotype. Myofibroblasts retain the capacity to proliferate and are resistant to apoptosis while secreting large amounts of extracellular matrix proteins, soluble growth factors/cytokines and extracellular oxidants. Soluble mediators and the insoluble matrix elaborated by these myofibroblasts may, in turn, lead to aberrant reepithelialization that perpetuates a feed-forward cycle. IPF fibroblasts/myofibroblasts and alveolar epithelial cells contribute to an imbalance in angiogenic chemokines that may promote neovascularization and aberrant angiogenesis in IPF. A “shift” in the host immune response, favoring a TH2 cytokine profile, has been postulated to contribute to initiation and/or progression of IPF.

Similar articles

Cited by

References

    1. Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994;149(2 Pt 1):450–4. - PubMed
    1. King TE, Jr., Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171–81. - PubMed
    1. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64. - PubMed
    1. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967–72. - PubMed
    1. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084–90. - PubMed

MeSH terms